 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Samsung BioLogics, a domestic pharmaceutical consignment development (CDMO) company, has won more than 1 trillion won in consignment production (CMO) contracts by June this year. Seven out of 10 global big pharma companies chose Samsung BioLogics.
According to the Financial Supervisory Service (FSS) on the 10th, Samsung BioLogics won an CMO worth $ 1.06 billion (about 1.28 trillion won) as of the 8th. Compared to last year, it advanced two months to surpass 1 trillion won in orders. This is due to the signing of seven contracts, including Eli Lilly and Pfizer, starting with a $ 27 million CMO contract with Glaxosmith Klein (GSK) on February 6.
Samsung BioLogics has secured seven of the world's top 10 pharmaceutical companies (based on sales ranking) as customers. Pfizer, Roche, Novartis, MSD, GSK, and BMS.
Five of the CMO contracts signed this year each exceed KRW 100 billion. Among them is a KRW 535 billion CMO contract signed by Samsung Biologics and Pfizer on the 8th. This is the largest contract ever made by Samsung Biologics.
Pfizer is the world's largest-selling global pharmaceutical company last year, with sales reaching 131.744 trillion won alone.
The two companies signed a biopharmaceutical CMO contract worth 241 billion won in March as their first contract. It then signed an additional partnership on the 8th.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
